It comprises four clinical subtypes: estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and human epidermal growth factor receptor-positive (HER2+) forms, and lack of expression any of the above is known as triple-negative breast cancer (TNBC). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.